August 9, 2018 News by Vijaya Iyer, PhD MedChew RX Shows Stability and Potential for Effectiveness in Early Tests, Company Reports AXIM BiotechĀ announced that tests done on itsĀ cannabinoid-based chewing gum āĀ MedChew RxĀ ā showed both product stability and effective release of medicinal molecules,Ā with a high percentage of itsĀ pharmaceutical ingredients available. These test results may be of importance, as the company is planning to bring MedChew Rx into clinical trials as a…
January 25, 2018 News by Ana Pena PhD Holland Approves Clinical Trial Plans for AXIM’s Cannabis-based Gum for MS Pain and Spasticity Dutch regulators have signed off onĀ AXIM Biotechnologies’Ā clinical trial plans forĀ a chewing gum that offers controlled release of cannabinoids to treat multiple sclerosis patients’ pain and spasticity. The Dutch Medicines Evaluation Board’s sign-off on MedChew Rx means AXIM can start trials. A leader in cannabinoid research, New York-based AXIM…
June 20, 2017 News by Patricia Silva, PhD AXIM Obtains More Financing for Its Cannabinoid Therapies for MS and Bowel Diseases AXIM BiotechnologiesĀ has secured an additional $4 million in institutional financing to advance clinical trials of itsĀ cannabinoid therapies forĀ multiple sclerosis (MS) andĀ irritable bowel syndrome. Some of the trials involve a chewing-gum therapy delivery system.Ā The financing will let the company continue developing a patented chewing-gum-delivered therapy for pain andĀ spasticity. AXIM…
May 3, 2017 News by Patricia Silva, PhD Axim Signs Deal to Advance Clinical Trials of Cannabis-based MedChew Rx Gum to Treat MS Pain Axim BiotechnologiesĀ recently announced that its U.K. partner, Quay Pharmaceuticals,Ā has secured licenses from the British Home Office to continue developing and importing its medicalĀ cannabinoid product MedChew Rx ā a potential treatment forĀ pain andĀ spasticityĀ in people with multiple sclerosis (MS), among other illnesses. MedChew Rx is a gum…
November 18, 2016 News by Patricia Silva, PhD AXIM Biotech to Get U.S. Patent Covering All Cannabinoids in Its Chewing Gums AXIM BiotechnologiesĀ announced that theĀ United States Patent and Trademark Office (USPTO) will be issuing a patent coveringĀ all cannabinoids ā both natural and synthetic ā Ā used in a chewing gum delivery system that may be included in itsĀ cannabinoid-containing, controlled-release chewing gum products. The USPTO has given the company aĀ Notice of…
November 7, 2016 News by Patricia Silva, PhD Testing Stages of Marijuana Gum to Treat Spasticity in MS Can Be Followed Online Medical MarijuanaĀ announced thatĀ Axim Biotechnologies,Ā aĀ cannabinoid-based product developer in which it owns a strategic interest, has released a product pipeline chart highlighting development timelines for its cannabinoid-based therapeutics, including those forĀ Ā multiple sclerosis (MS)Ā patients. The Ā chart illustrates the stage each drug is in, from preclinical testingĀ to, eventually, applications for regulatory…
November 2, 2016 News by Charles Moore AXIM Advances Clinical Trials for MS Relief with Medical Cannabinoid Chewing Gum AXIM BiotechĀ has closed on a private funding round that will enable itĀ to continue clinical trials for a variety of conditions, including its pharmaceutical candidate MedChew Rx, a patented cannabinoid release chewing gum for treating pain and spasticity in multiple sclerosis (MS). According to a press releaseĀ from SECFilings.com,…
October 28, 2016 News by Patricia Silva, PhD AXIM Moving Ahead with Testing of Cannabinoid Products, Including Chewing Gum for MS Patients AXIM Biotechnologies Ā announced it has secured financing from private sources to continue its testing of medicalĀ cannabinoid products as potential treatments forĀ multiple indications, includingĀ pain and spasticity in people with multiple sclerosis (MS). Specifically, AXIM Ā is testing pharmaceutical delivery systems andĀ active ingredients for itsĀ medical marijuana line. āThis financing provides us with…
January 11, 2016 News by Charles Moore Can Cannabinoid Chewing Gum Treat Multiple Sclerosis Pain and Spasticity? MedChew Rx, by AXIM Biotechnology,Ā the world’s first patented cannabinoid release chewing gum for pain and spasticity in multiple sclerosis (MS), is movingĀ into clinical testing. If all goes well, the company plans for a global release date ofĀ 2017. Medical cannabis is believed to have considerable promise as a therapy for…
August 24, 2015 News by Charles Moore Clinical Trials Study Cannabis Chewing Gum for MS-Associated Pain and Spasticity AXIM Biotechnologies, Inc. (AXIM)’s clinical trials testingĀ a new pharmaceutical-grade cannabis chewing gum treatment option for Multiple Sclerosis (MS) pain and spasticity are drawing lots of popular and specialty media attention, with reports in Multiple Sclerosis News Today, Marketwatch, Yahoo! Finance, Wall Street Journal, CNN Money,…
August 12, 2015 News by Charles Moore Could Multiple Sclerosis Sufferers Benefit From Cannabis Chewing Gum? AXIM Biotechnologies, Inc., a biotechnology company focused on global research, development and production of pharmaceutical, nutraceutical, food and cosmetic products derived from industrial hemp, has announced commencement of clinical development of its leading patented pharmaceutical chewing gum, MedChew RX, for registration as a drug for relieving pain and/or spasticity…